- Home
- SNCY vs SVRA Comparison
SNCY vs SVRA Comparison
Compare SNCY & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNCY | SVRA |
|---|---|---|
| Founded | 1982 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2021 | 2009 |
Fundamental Metrics
Financial Performance| Metric | SNCY | SVRA |
|---|---|---|
| Price | $16.84 | $5.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $19.29 | $7.33 |
| AVG Volume (30 Days) | 803.0K | ★ 1.5M |
| Earning Date | 04-30-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $1,126,769,000.00 | N/A |
| Revenue This Year | $9.52 | N/A |
| Revenue Next Year | $9.40 | $430.87 |
| P/E Ratio | $16.56 | ★ N/A |
| Revenue Growth | ★ 4.74 | N/A |
| 52 Week Low | $8.10 | $1.89 |
| 52 Week High | $22.29 | $7.01 |
Technical Indicators
Market Signals| Indicator | SNCY | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 39.93 |
| Support Level | $10.77 | $3.36 |
| Resistance Level | $18.28 | $6.10 |
| Average True Range (ATR) | 0.74 | 0.26 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 38.60 | 18.72 |
Price Performance
Historical ComparisonAbout SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).